FDA Accepts NDA For Omapro
The FDA has accepted ChemGenex Pharmaceuticals’ (ChemGenex) New Drug Application (NDA) for Omapro (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.